NCLAT: Can’t Dismiss Restoration App. if Filed in 30 Days from Date of Dismissal of Original App.  ||  Delhi HC: Communication between Parties through Whatsapp Constitute Valid Agreement  ||  Delhi HC Seeks Response from Govt. Over Penalties on Petrol Pumps Supplying Fuel to Old Vehicles  ||  Centre Notifies "Unified Waqf Management, Empowerment, Efficiency and Development Rules, 2025"  ||  Del. HC: Can’t Reject TM Owner’s Claim Merely because Defendant Could have Sought Removal of Mark  ||  Bombay HC: Cannot Treat Sole Director of OPC, Parallelly with Separate Legal Entity  ||  Delhi HC: Can Apply 'Family of Marks' Concept to Injunct Specific Marks  ||  HP HC: Can’t Set Aside Ex-Parte Decree for Mere Irregularity  ||  Cal. HC: Order by HC Bench Not Conferred With Determination by Roster is Void  ||  Calcutta HC: Purchase Order Including Arbitration Agreement to Prevail Over Tax Invoice Lacking it    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved